Objectives: To analyze the frequency of β S -globin haplotypes and alpha-thalassemia, andtheir influence on clinical manifestations and the hematological profile of children withsickle cell anemia. Method: The frequency of β S -globin haplotypes and alpha-thalassemia and any associationwith clinical and laboratorial manifestations were determined in 117 sickle cell anemiachildren aged 3–71 months. The confirmation of hemoglobin SS and determination of the haplotypes were achieved by polymerase chain reaction-restriction fragment length polymorphism, and alpha-thalassemia genotyping was by multiplex polymerase chain reaction (single-tube multiplex-polymerase chain reaction). Results: The genotype distribution of haplotypes was 43 (36.7%) Central African Republic/Benin, 41 (35.0%) Central African Republic/Central African Republic, 20 (17.0%) Rare/atypical, and 13 (11.1%) Benin/Benin. The frequency of the α3.7 deletion was 1.71% as homozygous (− α3.7/− α3.7) and 11.9% as heterozygous (− α3.7/− αα). The only significant association in respect to haplotypes was related to the mean corpuscular volume.The presence of alpha-thalassemia was significantly associated to decreases in meancorpuscular volume, mean corpuscular hemoglobin and reticulocyte count and to anincrease in the red blood cell count. There were no significant associations of β S -globin haplotypes and alpha-thalassemia with clinical manifestations. Conclusions: In the study population, the frequency of alpha-thalassemia was similar to published data in Brazil with the Central African Republic haplotype being the most common, followed by the Benin haplotype. β S -globin haplotypes and interaction between alpha-thalassemia and sickle cell anemia did not influence fetal hemoglobin concentrationsor the number of clinical manifestations.
Camilo-Araújo, R. F., Amancio, O. M. S., Figueiredo, M. S., Cabanãs-Pedro, A. C., & Braga, J. A. P. (2014). Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia. Revista Brasileira de Hematologia e Hemoterapia, 36(5), 334–339. https://doi.org/10.1016/j.bjhh.2014.06.002